| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Pharmaceuticals R&D, Amersham International plc, Amersham, Buckinghamshire, UK
Department of Nuclear Medicine, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, UK
Department of Cardiology, Northwick Park Hospital and Section of Medical Physics, Clinical Research Centre, Harrow, Middlesex, UK
Correspondence: For correspondence or reprints contact: Brian Higley, Pharmaceuticals R&D, Amersham Intl. plc, White Lion Rd., Amersham, Buckinghamshire, HP7, 9LL, UK.
ABSTRACT
A novel 99mTc complex (1,2-bis[bis(2-ethoxyethyl)phosphino] ethane, 99mTc-tetrofosmin) has been developed to replace 201Tl in myocardial perfusion imaging. Biodistribution, safety and dosimetry of 99mTc-tetrofosmin were studied in 12 male volunteers, each at rest and during exercise. Safety parameters measured to 48 hr postinjection revealed no clinically significant long-term drug-related changes. Biodistribution was studied by acquiring whole-body or serial static images up to 48 hr postinjection. Technetium-99m-tetrofosmin shows good heart uptake (1.2%) with retention. Clearance is excellent from blood (<5% by 10 min), liver (<4.5% by 60 min) and lung. Sequestration of activity by skeletal muscle is enhanced during exercise. Radiation dosimetry calculations indicate that the effective dose, assuming a 3.5 hr bladder voiding period, is 32.9 x 10–3 rad/mCi (8.9 x 10–3 mSv/MBq) at rest and 26.7 x 10–3 rad/mCi (7.1 x 10–3 mSv/MBq) after exercise. Technetium-99m-tetrofosmin can produce high quality myocardial images from 5 min to several hours postinjection.
This article has been cited by other articles:
|
|
 |
|
  M. G. Stabin Radiopharmaceuticals for Nuclear Cardiology: Radiation Dosimetry, Uncertainties, and Risk J. Nucl. Med., September 1, 2008; 49(9): 1555 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Cittanti, L. Uccelli, M. Pasquali, A. Boschi, C. Flammia, E. Bagatin, M. Casali, M. G. Stabin, L. Feggi, M. Giganti, et al. Whole-Body Biodistribution and Radiation Dosimetry of the New Cardiac Tracer 99mTc-N-DBODC J. Nucl. Med., August 1, 2008; 49(8): 1299 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Giorgetti, M. Rossi, M. Stanislao, G. Valle, P. Bertolaccini, A. Maneschi, R. Giubbini, M. L. De Rimini, M. Mazzanti, M. Cappagli, et al. Feasibility and Diagnostic Accuracy of a Gated SPECT Early-Imaging Protocol: A Multicenter Study of the Myoview Imaging Optimization Group J. Nucl. Med., October 1, 2007; 48(10): 1670 - 1675. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Madar, H. Ravert, A. DiPaula, Y. Du, R. F. Dannals, and L. Becker Assessment of Severity of Coronary Artery Stenosis in a Canine Model Using the PET Agent 18F-Fluorobenzyl Triphenyl Phosphonium: Comparison with 99mTc-Tetrofosmin J. Nucl. Med., June 1, 2007; 48(6): 1021 - 1030. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Madar, H. T. Ravert, Y. Du, J. Hilton, L. Volokh, R. F. Dannals, J. J. Frost, and J. M. Hare Characterization of Uptake of the New PET Imaging Compound 18F-Fluorobenzyl Triphenyl Phosphonium in Dog Myocardium J. Nucl. Med., August 1, 2006; 47(8): 1359 - 1366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hatada, L. M. Riou, M. Ruiz, Y. Yamamichi, A. Duatti, R. L. Lima, A. R. Goode, D. D. Watson, G. A. Beller, and D. K. Glover 99mTc-N-DBODC5, a New Myocardial Perfusion Imaging Agent with Rapid Liver Clearance: Comparison with 99mTc-Sestamibi and 99mTc-Tetrofosmin in Rats J. Nucl. Med., December 1, 2004; 45(12): 2095 - 2101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Schillaci, A. Spanu, F. Scopinaro, F. Monteleone, M. E. Solinas, P. Volpino, P. Pirina, P. Marongiu, V. Cangemi, and G. Madeddu Mediastinal Lymph Node Involvement in Non-Small Cell Lung Cancer: Evaluation with 99mTc-Tetrofosmin SPECT and Comparison with CT J. Nucl. Med., August 1, 2003; 44(8): 1219 - 1224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Matsuo, S. Watanabe, T. Segawa, S. Yasuda, T. Hirose, M. Iwama, S. Tanaka, T. Yamaki, Y. Matsuno, M. Tomita, et al. Evidence of pharmacologic preconditioning during PTCA by intravenous pretreatment with ATP-sensitive K+ channel opener nicorandil Eur. Heart J., July 2, 2003; 24(14): 1296 - 1303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Iida, T. Hayashi, S. Eberl, and H. Saji Quantification in SPECT Cardiac Imaging J. Nucl. Med., January 1, 2003; 44(1): 40 - 42. [Full Text] [PDF]
|
|
|
|
|
|
M. Nanasato, A. Ando, S. Isobe, M. Nonokawa, H. Hirayama, N. Tsuboi, T. Ito, M. Hirai, M. Yokota, and H. Saito Evaluation of Left Ventricular Function Using Electrocardiographically Gated Myocardial SPECT with 123I-Labeled Fatty Acid Analog J. Nucl. Med., December 1, 2001; 42(12): 1747 - 1756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Fagret, C. Ghezzi, and G. Vanzetto 99mTc-N-NOET Imaging for Myocardial Perfusion: Can It Offer More Than We Already Have? J. Nucl. Med., September 1, 2001; 42(9): 1395 - 1396. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Matsunari, G. Boning, S. I. Ziegler, S. G. Nekolla, J. C. Stollfuss, I. Kosa, E. P. Ficaro, and M. Schwaiger Attenuation-corrected 99mTc-tetrofosmin single-photon emission computed tomography in the detection of viable myocardium: comparison with positron emission tomography using 18F-fluorodeoxyglucose J. Am. Coll. Cardiol., October 1, 1998; 32(4): 927 - 935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. L. Zaret, P. Rigo, F. J.T. Wackers, R. C. Hendel, S. H. Braat, A. S. Iskandrian, B. S. Sridhara, D. Jain, R. Itti, A. N. Serafini, et al. Myocardial Perfusion Imaging With 99mTc Tetrofosmin : Comparison to 201Tl Imaging and Coronary Angiography in a Phase III Multicenter Trial Circulation, January 15, 1995; 91(2): 313 - 319. [Abstract] [Full Text]
|
|
|
|
|
|
D. D. Miller The Growing Flood of Technetium-99m Myocardial Perfusion Agents : More Water . . . or More Mud? Circulation, January 15, 1995; 91(2): 555 - 558. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
